Week of June 29, 2009

Mark Rosenberg, MD
Director and Founder of the Institute for Anti‐Aging in South Florida.

Dr. Rosenberg received his undergraduate degree from University of Pennsylvania and graduated from Georgetown University School of Medicine. He completed his residency in emergency medicine at Brooke Army Medical Center, where he won the award of "Teacher and Resident of the Year."

He is a diplomate of the American Academy of Anti‐Aging Medicine. He is a highly sought‐after speaker on topics such as integrative cancer therapy and anti‐aging medicine.

At the upcoming Anti-Aging Conference: Clinical Applications for In-Office Procedures in San Jose, California (September 9-12, 2009), Dr. Rosenberg will present, Non‐Toxic Cancer Therapies, on Friday, September 11th.

For more information call the A4M today; 1-888-997-0112.
Continue reading…

Campaigns that cast the tobacco industry in a negative light are far more effective at encouraging young people to stop smoking than traditional campaigns that focus on health hazards, the first-ever study on attitudes about the tobacco industry finds. Continue reading…

The utility of hormonal replacement therapy and other proactive longevity medicine practiced by A4M physicians not only improves the quality of life in patients, it also prevents unnecessary depression, anxiety and insomnia disorders all of which cause subsequent addiction. Continue reading…

A study detailed in the upcoming February issue of Nature Neuroscience suggests that individual nerve cells located in the front part of the brain, called neurons, are able to hold memories on their own for up to a minute. Continue reading…

A novel experiment conducted by Carnegie Mellon University Professor George Loewenstein and colleagues may explain why people try a drug, such as heroin, for the first time despite ample evidence that it is addictive. The results of the study, which are being published in the Journal of Health Economics, reveal that even longtime addicts underestimate the influence that drug cravings have over their behavior. Continue reading…

A long-term research project at the University of Missouri-Columbia is producing valuable information about alcoholism and individuals who are affected by a family history of the disease. MU psychology researchers, now several years into a multi-year study, have discovered that individuals from alcoholic homes maintain personality traits that could eventually lead to alcohol dependency. Continue reading…

After years of progress in reducing adult smoking rates, a recent study issued by the Centers for Disease Control and Prevention (CDC) indicates that the reduction in U.S. adult smoking rates may have stalled. Between 2004 and 2005, there was no observed change in U.S. adult smoking rates. According to an article in this week's issue of CDC's Morbidity and Mortality Weekly Report (MMWR), 20.9 percent-45.1 million people-in the United States are current smokers, the same rate as in 2004. Continue reading…

Smokers with a damaged insula -- a region in the brain linked to emotion and feelings -- quit smoking easily and immediately, according to a study in the Jan. 26 issue of the journal Science. The study provides direct evidence of smoking's grip on the brain. It also raises the possibility that other addictive behaviors may have an equally strong hold on neural circuits for pleasure. Continue reading…

Most people realize that too much alcohol can lead to multiple health problems, injuries and violence. Numerous statistics support the accuracy of this perception. Many people also assume that a substantial proportion of people who drink to excess are probably alcoholics. This may not be accurate. A recent study of the general population in New Mexico reveals that, in fact, most alcohol-related problems may be due to excessive drinking -- especially binge drinking -- among persons who are not alcoholics. Continue reading…

Smokers who use the prescription-only anti-smoking agent varenicline triple their likelihood of successfully kicking the habit, compared with trying to quit without medication, a new review concludes. Pfizer's varenicline was approved in 2006 by the US FDA under the trade name Chantix and by European regulators under the trade name Champix. The drug partially stimulates nicotine receptors in the brain, which helps reduce nicotine withdrawal symptoms. Continue reading…